Growth Hormone Secretion
CJC-1295 + Ipamorelin
Mod GRF(1-29) + Ipamorelin; CJC no-DAC + Ipa; GHRH+GHRP blend
GHRH analog + selective GHRP blend (GH-secretagogue stack)
This CJC-1295 + Ipamorelin entry draws on 3 cited sources published 1998 to 2006. The evidence available is graded Anecdotal + Animal Studies on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- GHRH analog + selective GHRP blend (GH-secretagogue stack)
- Drug class
- Growth Hormone Secretion
- Structure
- Co-formulated vial: ~2 mg CJC-1295 no-DAC (29-aa GHRH analog) + ~2 mg Ipamorelin (pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH2)
- Route
- SC injection
- Half-life
- CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs
- Evidence tier
- Anecdotal + Animal Studies
- Availability
- Compounding Restricted
- Research depth
- 5 indexed citations →
Mechanism of action
Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).
Reported areas of research
Layered pituitary GH release; improved sleep architecture; recovery and lean body composition support; lower cortisol/prolactin signal than GHRH + GHRP-6 alternatives
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication
Compared with
CJC-1295 + Ipamorelin has published head-to-head comparisons with 10 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
- CJC-1295 + Ipamorelin vs CJC-1295
- CJC-1295 + Ipamorelin vs GHRP-2
- CJC-1295 + Ipamorelin vs GHRP-6
- CJC-1295 + Ipamorelin vs Hexarelin
- CJC-1295 + Ipamorelin vs Hulk Stack
- CJC-1295 + Ipamorelin vs Ipamorelin
- CJC-1295 + Ipamorelin vs MK-677
- CJC-1295 + Ipamorelin vs Sermorelin
- CJC-1295 + Ipamorelin vs Tesamorelin
- CJC-1295 + Ipamorelin vs Tesamorelin + Ipamorelin
Frequently asked questions
What dosing is reported for CJC-1295 + Ipamorelin in research literature?
Published peptide research reports the following dosing approach for CJC-1295 + Ipamorelin: 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off. This is a research reference, not a clinical recommendation.
How is CJC-1295 + Ipamorelin administered in research?
CJC-1295 + Ipamorelin is administered via the following routes in published studies: SC injection.
What is the reported half-life of CJC-1295 + Ipamorelin?
The reported half-life of CJC-1295 + Ipamorelin is CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs.
Is CJC-1295 + Ipamorelin FDA-approved?
No. CJC-1295 + Ipamorelin is not an FDA-approved drug. PeptideHelper.org catalog status: Compounding Restricted.
What level of evidence supports CJC-1295 + Ipamorelin?
The current evidence base for CJC-1295 + Ipamorelin is best characterised as: Anecdotal + Animal Studies. See the methodology page for the full evidence-tier rubric.
What side effects are reported for CJC-1295 + Ipamorelin?
Known concerns reported in the literature for CJC-1295 + Ipamorelin include: Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication. Always consult a qualified clinician before any human use.
Is there anyone who should not use CJC-1295 + Ipamorelin?
No formal contraindications are established for CJC-1295 + Ipamorelin, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication. Always consult a qualified clinician before any human use.
How does CJC-1295 + Ipamorelin work?
The mechanism of action reported for CJC-1295 + Ipamorelin in the literature: Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm)..
What is CJC-1295 + Ipamorelin studied for?
CJC-1295 + Ipamorelin has been studied in the published literature for: Layered pituitary GH release; improved sleep architecture; recovery and lean body composition support; lower cortisol/prolactin signal than GHRH + GHRP-6 alternatives. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin is classified as: GHRH analog + selective GHRP blend (GH-secretagogue stack). Also known as: Mod GRF(1-29) + Ipamorelin; CJC no-DAC + Ipa; GHRH+GHRP blend.
Drug class
- GHRH peptides, see all peptides tagged GHRH.
- GHRP peptides, see all peptides tagged GHRP.
- GH-secretagogue peptides, see all peptides tagged GH-secretagogue.
Research focus area
All peptides studied for Growth Hormone Secretion, ranked by evidence tier and regulatory status.
Primary sources
- Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab 2006. PMID 16352683
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998. PMID 9849822
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006. PMID 18046911
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…